Imatinib is a highlyselective inhibitor of the Abl, BCRABL, PDGFRα/β, and KIT kinases; itis used in BCRABL- positive leukemia and GISTs carrying mutations inKIT and PDGFR. Imatinib is used incombination with other anti-leukemic drugs in AML. Here, ABL1 is linked to leukemia.